Innovations in the detection, diagnosis, and risk assessment of suspicious tumors and risk assessment are expected to stimulate the PET radiotracer market.Wilmington, Delaware, United States, July 28, 2023 (GLOBE NEWSWIRE) According to TMR, PET radiotracers are expected to rise at a CAGR of 8.5% by 2031. A recent market study estimates that, by 2031, the global PET radiotracer market is expected to reach US$ 3.2 billion. Oncology and neuroscience are the primary fields in which PET radiotrace
Molecular Imaging Assess Breast Cancer Treatment Efficacy by Angela Mohan on February 17, 2021 at 12:11 PM
Journal of Nuclear Medicine.
Nearly two-thirds of invasive breast cancers are ER-positive, and endocrine therapy is the mainstay of treatment for these tumors because of its favorable toxicity profile and efficacy. Should cancer progress in these patients, however, salvage endocrine therapy with molecularly targeted agents or chemotherapy can help. In some ER-positive breast cancer patients, cancer progression can be a result of a gradual resistance to endocrine therapy, noted Hannah M Linden, MD, FACP, Athena Distinguished Professor and breast medical oncologist at the University of Washington Fred Hutchison Cancer Research Center and Seattle Cancer Care Alliance in Seattle, Washington.